Skip to content
DataLookout
Menu

NCT07466498

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Nov 1, 2026 to Dec 1, 2026
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 67 words
    • Study description expanded, about 59 words
  2. Notable Recruitment opened
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints: details revised at 2 of 9 entries
    • Site details revised
  3. Notable Sponsor changed: University of Washington to Fred Hutchinson Cancer Centerv3
  4. Notable Start date: Aug 1, 2026 to Nov 1, 2026v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in mean daily hot flash score
Timeframe: From baseline to a minimum of 12 weeks combination therapy

Secondary (9)

Change in quality of life (QOL) domains
Bone mineral density
Changes in metabolic parameters: Mean change in hemoglobin A1c
Changes in metabolic parameters: Mean change in lipid panel values
Changes in sleep patterns and sleep quality
Show 4 moreShow less
Incidence of adverse events
Time to radiographic progression
Time to prostate specific antigen (PSA) progression
Changes in immune cell composition

Arms and interventions

Cohort 1 (LHRH agonist/antagonist and ARSI)Active comparator

Patients receive standard of care LHRH agonist or LHRH antagonist according to the Food and Drug Administration approved dose and schedule in the absence of disease progression or unacceptable toxicity. Starting 4 weeks after initiation of LHRH agonist/antagonist, patients also receive ARSI per physician's choice for a minimum of 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with a median daily hot flash score ≥ 6 after 12 weeks of therapy may crossover to cohort 2. Patients undergo CT scan or MRI, bone scan, DEXA scan and blood sample collection throughout the study.

Cohort 2 (Estrogen and ARSI)Experimental

Patients receive estrogen via four transdermal patches BIW on days 1, 4, 8, 12, 16, 20, 24 and 28 of cycle 1. Once castrate levels of testosterone are confirmed (\< 20 ng/dL), patients receive three patches BIW on days 1, 4, 8, 12, 16, 20, 24 and 28 of cycles thereafter. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose testosterone levels rise above castrate levels at any time while receiving three patches BIW then increase to four patches BIW. Starting 4 weeks after initiation of transdermal estrogen, patients also receive ARSI per physician's choice for a minimum of 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI, bone scan, DEXA scan and blood sample collection throughout the study.

Drugs: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen

Procedures: Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Magnetic Resonance Imaging, Biospecimen Collection

Biologicals: Gonadotropin-releasing Hormone Analog

Other: Survey Administration

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States